普萘洛尔治疗婴幼儿眼部血管瘤临床观察  

Clinical observation for treating infantile ophthalmic hemangioma by oral propranolol

作　　者：黄静[1] 项道满[1] Huang Jing;Xiang Daoman(Guangzhou Women and Childrens Medical Center,Guangzhou,Guangdong 510000,China)

机构地区：[1]广州市妇女儿童医院中心(广州市儿童医院)

出　　处：《临床眼科杂志》2019年第3期263-265,共3页Journal of Clinical Ophthalmology

摘　　要：目的观察门诊患者口服普萘洛尔治疗婴幼儿眼部血管瘤的临床疗效及安全性。方法前瞻性研究。分析2016年2月至2018年4月儿童眼科门诊治疗的66例眼部血管瘤患儿服药后瘤体大小、颜色变化及不良反应,评价临床疗效和安全性。结果 83.3%患儿1周内瘤体颜色变浅或充盈度较前下降,疗效Ⅰ级4例(6.1%),Ⅱ级7例(10.6%),Ⅲ级9例(13.6%),Ⅳ级46例(69.7%)。平均治疗6.9个月,长疗程组疗效优于短疗程组,且用药4~12个月的临床疗效优于其他疗程组。治疗过程中1例腹泻外,未发现明显副作用。停药后瘤体反弹1例,再次用药后Ⅳ级疗效。结论口服普萘洛尔作为一线用药治疗婴幼儿眼部血管瘤在门诊同样安全有效。Objective To observe the clinical efficacy and safety of oral propranolol in the treatment of infantile ocular hemangioma. Methods A prospective study was conducted to analyze the size, color changes and adverse reactions of 66 children with ocular hemangioma treated in pediatric ophthalmic outpatient department from February 2016 to April 2018, and to evaluate the clinical efficacy and safety.Results 83.3% of children in 1 weeks tumors had the color becomes shallow or filling degree of the previous decline, curative effect Ⅰ level 4 cases(6.1%),Ⅱ level 7 cases(10.6%),Ⅲ level 9 cases(13.6%), grade Ⅳ 46 cases(69.7%). The average treatment time was 6.9 months. The effect of the long course group was better than that of the short course group, and the clinical effect of 4~12 months was better than that of the other treatment groups. No obvious side effects were found in 1 case of diarrhea during the treatment. Tumors had rebounded after the drug was stopped in 1 case, again after Ⅳ curative effect.Conclusions Oral propranolol as a first-line treatment for infantile ocular hemangioma is equally safe and effective in the clinic.

关 键 词：普萘洛尔 婴幼儿 眼 血管瘤 

分 类 号：R739.7[医药卫生—肿瘤]